DYRK1A antibody (AA 674-763)

Catalog No. ABIN560675

The Mouse Monoclonal anti-DYRK1A antibody has been validated for WB and ELISA. It is suitable to detect DYRK1A in samples from Human. There are 39+ publications available.

Quick Overview for DYRK1A antibody (AA 674-763) (ABIN560675)

Target: DYRK1A (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 1A (DYRK1A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This DYRK1A antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Clone: 7D10

Product Details anti-DYRK1A Antibody

Binding Specificity: AA 674-763

Purpose: Mouse monoclonal antibody raised against a partial recombinant DYRK1A.

Sequence: NQGNQAYQNR PVAANTLDFG QNGAMDVNLT VYSNPRQETG IAGHPTYQFS ANTGPAHYMT EGHLTMRQGA DREESPMTGV CVQQSPVASS

Cross-Reactivity: Human, Mouse, Rat

Characteristics: Antibody Reactive Against Recombinant Protein.

Immunogen: DYRK1A (NP_001387, 674 a.a. ~ 763 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Isotype: IgG2b

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: In 1x PBS, pH 7.4

Handling Advice: Aliquot to avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

References for anti-DYRK1A antibody (ABIN560675)

Rabaneda, Geribaldi-Doldán, Murillo-Carretero, Carrasco, Martínez-Salas, Verástegui, Castro: "Altered regulation of the Spry2/Dyrk1A/PP2A triad by homocysteine impairs neural progenitor cell proliferation." in: Biochimica et biophysica acta, Vol. 1863, Issue 12, pp. 3015-3026, (2016) (PubMed).

Souchet, Latour, Gu, Daubigney, Paul, Delabar, Janel: "Molecular rescue of DYRK1A overexpression in cystathionine beta synthase-deficient mouse brain by enriched environment combined with voluntary exercise." in: Journal of molecular neuroscience : MN, Vol. 55, Issue 2, pp. 318-23, (2015) (PubMed).

Thompson, Bhansali, Diebold, Cook, Stolzenburg, Casagrande, Besson, Leblond, Désiré, Malinge, Crispino: "DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3." in: The Journal of experimental medicine, Vol. 212, Issue 6, pp. 953-70, (2015) (PubMed).

Najas, Arranz, Lochhead, Ashford, Oxley, Delabar, Cook, Barallobre, Arbonés: "DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome." in: EBioMedicine, Vol. 2, Issue 2, pp. 120-34, (2015) (PubMed).

Blazek, Abeysekera, Li, Roper: "Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a." in: Human molecular genetics, Vol. 24, Issue 20, pp. 5687-96, (2015) (PubMed).

Stringer, Abeysekera, Dria, Roper, Goodlett: "Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model." in: Pharmacology, biochemistry, and behavior, Vol. 138, pp. 70-9, (2015) (PubMed).

Fant, Durieu, Chicanne, Payrastre, Sbrissa, Shisheva, Limanton, Carreaux, Bazureau, Meijer: "cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease." in: Molecular pharmacology, Vol. 85, Issue 3, pp. 441-50, (2014) (PubMed).

Hibaoui, Grad, Letourneau, Sailani, Dahoun, Santoni, Gimelli, Guipponi, Pelte, Béna, Antonarakis, Feki: "Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21." in: EMBO molecular medicine, Vol. 6, Issue 2, pp. 259-77, (2014) (PubMed).

Rachdi, Kariyawasam, Guez, Aïello, Arbonés, Janel, Delabar, Polak, Scharfmann: "Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass." in: Diabetologia, Vol. 57, Issue 5, pp. 960-9, (2014) (PubMed).

García-Cerro, Martínez, Vidal, Corrales, Flórez, Vidal, Rueda, Arbonés, Martínez-Cué: "Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome." in: PLoS ONE, Vol. 9, Issue 9, pp. e106572, (2014) (PubMed).

Thomazeau, Lassalle, Iafrati, Souchet, Guedj, Janel, Chavis, Delabar, Manzoni: "Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 34, Issue 4, pp. 1138-47, (2014) (PubMed).

Janel, Sarazin, Corlier, Corne, de Souza, Hamelin, Aka, Lagarde, Blehaut, Hindié, Rain, Arbones, Dubois, Potier, Bottlaender, Delabar: "Plasma DYRK1A as a novel risk factor for Alzheimer's disease." in: Translational psychiatry, Vol. 4, pp. e425, (2014) (PubMed).

Grau, Arató, Fernández-Fernández, Valderrama, Sindreu, Fillat, Ferrer, de la Luna, Altafaj: "DYRK1A-mediated phosphorylation of GluN2A at Ser(1048) regulates the surface expression and channel activity of GluN1/GluN2A receptors." in: Frontiers in cellular neuroscience, Vol. 8, pp. 331, (2014) (PubMed).

Planque, Dairou, Noll, Bui, Ripoll, Guedj, Delabar, Janel: "Mice deficient in cystathionine beta synthase display increased Dyrk1A and SAHH activities in brain." in: Journal of molecular neuroscience : MN, Vol. 50, Issue 1, pp. 1-6, (2013) (PubMed).

Abekhoukh, Planque, Ripoll, Urbaniak, Paul, Delabar, Janel: "Dyrk1A, a serine/threonine kinase, is involved in ERK and Akt activation in the brain of hyperhomocysteinemic mice." in: Molecular neurobiology, Vol. 47, Issue 1, pp. 105-16, (2013) (PubMed).

Altafaj, Martín, Ortiz-Abalia, Valderrama, Lao-Peregrín, Dierssen, Fillat: "Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome." in: Neurobiology of disease, Vol. 52, pp. 117-27, (2013) (PubMed).

Arque, Casanovas, Dierssen: "Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome." in: PLoS ONE, Vol. 8, Issue 1, pp. e54285, (2013) (PubMed).

Tlili, Jacobs, de Koning, Mohamed, Bui, Dairou, Belin, Ducros, Dubois, Paul, Delabar, De Geest, Janel: "Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice." in: Biochimica et biophysica acta, Vol. 1832, Issue 6, pp. 718-28, (2013) (PubMed).

Laguna, Barallobre, Marchena, Mateus, Ramírez, Martínez-Cue, Delabar, Castelo-Branco, de la Villa, Arbonés: "Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome." in: Human molecular genetics, Vol. 22, Issue 14, pp. 2775-84, (2013) (PubMed).

Stefos, Soppa, Dierssen, Becker: "NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect." in: PLoS ONE, Vol. 8, Issue 6, pp. e67470, (2013) (PubMed).

Target Details for DYRK1A

Target: DYRK1A (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 1A (DYRK1A))

Alternative Name: DYRK1A

Background: Full Gene Name: dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Synonyms: DYRK,DYRK1,HP86,MNB,MNBH

Gene ID: 1859

NCBI Accession: NM_001396

Pathways: Mitotic G1-G1/S Phases